These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 17014005

  • 1. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 2. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA.
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [Abstract] [Full Text] [Related]

  • 3. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
    Dahlqvist SR, Engstrand S, Berglin E, Johnson O.
    Scand J Rheumatol; 2006 May; 35(2):107-11. PubMed ID: 16641043
    [Abstract] [Full Text] [Related]

  • 4. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 5. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis.
    Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):1004-7. PubMed ID: 12635469
    [Abstract] [Full Text] [Related]

  • 6. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, Radstake TR, Netea MG, Roest M, Stalenhoef AF.
    Ann Rheum Dis; 2009 Jun 30; 68(6):868-72. PubMed ID: 18635596
    [Abstract] [Full Text] [Related]

  • 7. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
    van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, van der Horst-Bruinsma IE, Hazenberg BP, van de Stadt RJ, Wolbink GJ, Nurmohamed MT.
    Arthritis Rheum; 2009 May 30; 60(5):1324-30. PubMed ID: 19404933
    [Abstract] [Full Text] [Related]

  • 8. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C, van den Hoogen FH, Radstake TR, Netea MG, Eijsbouts AE, den Heijer M, van der Meer JW, van Riel PL, Stalenhoef AF, Barrera P.
    Ann Rheum Dis; 2007 Nov 30; 66(11):1503-7. PubMed ID: 17472994
    [Abstract] [Full Text] [Related]

  • 9. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
    Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP.
    Arthritis Rheum; 2010 Jan 30; 62(1):150-8. PubMed ID: 20039407
    [Abstract] [Full Text] [Related]

  • 10. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 11. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec 15; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 12. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis.
    Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D.
    Clin Chim Acta; 2006 Mar 15; 365(1-2):143-8. PubMed ID: 16176811
    [Abstract] [Full Text] [Related]

  • 13. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S, Hafström I, Werner S, Carlström K, Tengstrand B.
    J Rheumatol; 2007 Jul 15; 34(7):1451-8. PubMed ID: 17477470
    [Abstract] [Full Text] [Related]

  • 14. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun 15; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 15. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun 15; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 16. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
    García-Gómez C, Nolla JM, Valverde J, Narváez J, Corbella E, Pintó X.
    Eur J Clin Invest; 2008 Sep 15; 38(9):686-92. PubMed ID: 18837746
    [Abstract] [Full Text] [Related]

  • 17. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 15; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 18. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 15; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 19. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2009 Mar 15; 21(3):283-8. PubMed ID: 19279474
    [Abstract] [Full Text] [Related]

  • 20. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.